PMID- 20081875
OWN - NLM
STAT- MEDLINE
DCOM- 20100308
LR  - 20211020
IS  - 2042-0226 (Electronic)
IS  - 1672-7681 (Print)
IS  - 1672-7681 (Linking)
VI  - 7
IP  - 1
DP  - 2010 Jan
TI  - CD40-activated B cells are more potent than immature dendritic cells to induce 
      and expand CD4(+) regulatory T cells.
PG  - 44-50
LID - 10.1038/cmi.2009.103 [doi]
AB  - CD4(+) regulatory T cells (Tregs) play an important role in maintaining immune 
      tolerance by suppressing pathologic immune responses. The generation of large 
      numbers of antigen-specific Tregs ex vivo is critical for the development of 
      clinical immunotherapy based on the adoptive transfer of Tregs. Both 
      CD40-activated B cells (CD40-B) and immature dendritic cells (imDCs) have been 
      used as professional antigen-presenting cells (APCs) to generate antigen-specific 
      Tregs. However, the efficiencies of CD40-B and imDCs to generate CD4(+) Tregs 
      have not been compared directly and the mechanism driving the generation of these 
      Tregs remains largely unknown. In this study, we found that CD40-B exhibited 
      mature phenotypes and were more able to induce and expand CD4(high)CD25(+) Tregs 
      than imDCs. Moreover, Tregs induced by CD40-B had greater suppressive capacity 
      than those induced by imDCs. The generation of CD4(high)CD25(+) Tregs by CD40-B 
      and imDCs is cell-cell contact dependent and partially relies on the expression 
      of human leukocyte antigen (HLA)-DR and CD80/86. Differences in CD4(high)CD25(+) 
      Treg generation efficiency were largely explained by the production of endogenous 
      IL-2 by CD40-B. Our results suggest that CD40-B is better able to generate large 
      numbers of antigen-specific Tregs than imDCs. Additionally, using CD40-B to 
      generate Tregs may accelerate the clinical use of Treg-based immunotherapy in the 
      treatment of allograft rejection, graft versus host disease (GVHD) and autoimmune 
      diseases.
FAU - Zheng, Jian
AU  - Zheng J
AD  - Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of 
      Medicine, University of Hong Kong, Hong Kong, China.
FAU - Liu, Yinping
AU  - Liu Y
FAU - Lau, Yu-Lung
AU  - Lau YL
FAU - Tu, Wenwei
AU  - Tu W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Cell Mol Immunol
JT  - Cellular & molecular immunology
JID - 101242872
RN  - 0 (CD40 Antigens)
RN  - 0 (Interleukin-2 Receptor alpha Subunit)
SB  - IM
MH  - B-Lymphocytes/*immunology
MH  - CD40 Antigens/*immunology
MH  - *Cell Communication
MH  - *Cell Differentiation
MH  - Coculture Techniques
MH  - Dendritic Cells/cytology/*immunology
MH  - Humans
MH  - Interleukin-2 Receptor alpha Subunit/immunology
MH  - T-Lymphocytes, Regulatory/cytology/*immunology
PMC - PMC4003254
EDAT- 2010/01/19 06:00
MHDA- 2010/03/10 06:00
PMCR- 2010/01/01
CRDT- 2010/01/19 06:00
PHST- 2010/01/19 06:00 [entrez]
PHST- 2010/01/19 06:00 [pubmed]
PHST- 2010/03/10 06:00 [medline]
PHST- 2010/01/01 00:00 [pmc-release]
AID - cmi2009103 [pii]
AID - 10.1038/cmi.2009.103 [doi]
PST - ppublish
SO  - Cell Mol Immunol. 2010 Jan;7(1):44-50. doi: 10.1038/cmi.2009.103.